| Jiang, Zefei |
NCT04514419: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel |
|
|
| Recruiting | 3 | 408 | RoW | HS627, Trastuzumab + HS627 + Docetaxel, Pertuzumab, Trastuzumab Pertuzumab Docetaxel | Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd | Breast Cancer | 11/21 | 11/21 | | |
TQB3616-III-01, NCT05375461: TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail |
|
|
| Active, not recruiting | 3 | 287 | RoW | TQB3616 capsules, TQB3616-matching placebo, Fluvestrin injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive,HER2-negative in Advanced Breast Cancer | 01/24 | 12/25 | | |
| Recruiting | 3 | 224 | RoW | DB-1303/BNT323, T-DM1 | DualityBio Inc., BioNTech SE | HER2-positive Breast Cancer | 02/26 | 02/26 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
CAPItrue, NCT06635447: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 560 | RoW | Capivasertib, AZD5363, Fulvestrant | AstraZeneca | Breast Cancer | 04/26 | 04/26 | | |
MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 350 | RoW | MRG002, Trastuzumab Emtansine for Injection | Shanghai Miracogen Inc. | Advanced Breast Cancer, Metastatic Breast Cancer | 09/23 | 10/23 | | |
NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 414 | RoW | Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine | Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Triple Negative Breast Cancer, Nab-paclitaxel | 06/22 | 09/22 | | |
| Recruiting | 2 | 99 | RoW | MRG002 | Shanghai Miracogen Inc. | Breast Cancer With Liver Metastases | 12/22 | 10/23 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) |
|
|
| Recruiting | 2 | 66 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced or Metastatic Breast Cancer | 02/23 | 02/23 | | |
NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC |
|
|
| Terminated | 2 | 9 | RoW | Chiauranib, capecitabine | Chipscreen Biosciences, Ltd. | Triple-negative Breast Cancer | 10/24 | 11/24 | | |
NCT06167694: Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer |
|
|
| Recruiting | 1/2 | 146 | RoW | HRS-8080; Dalpiciclib Isethionate Tablets | Shandong Suncadia Medicine Co., Ltd. | Unresectable or Metastatic Breast Cancer | 10/25 | 12/25 | | |
NCT05145179: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors |
|
|
| Not yet recruiting | 1 | 162 | NA | SSGJ-705 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Receptor, ErbB-2 | 12/23 | 06/24 | | |
| Not yet recruiting | 1 | 50 | RoW | QLS12004 | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 05/24 | 05/25 | | |
